Amends TCA Title 53; Title 63 and Title 68.

Tennessee SB0152 authorizes patients with severe chronic diseases or terminal illnesses to access investigational stem cell treatments that are currently under clinical investigation but not yet FDA-approved, provided specific criteria are met. The bill affects patients, their treating physicians, and regulatory bodies, establishing requirements for informed consent and protections for physicians recommending such treatments. Key provisions include the development of rules by the commissioner of health to define eligible medical conditions and safeguards against punitive actions against physicians for recommending these treatments.